| KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements YZ Au, M Gu, E De Braekeleer, M Gozdecka, D Aspris, Y Tarumoto, ... Leukemia 35 (4), 1012-1022, 2021 | 29 | 2021 |
| Peptide-based PROTAC: the predator of pathological proteins YZ Au, T Wang, LH Sigua, J Qi Cell chemical biology 27 (6), 637-639, 2020 | 21 | 2020 |
| Towards closed-loop integration of point-of-care technologies EKW Tan, YZ Au, GK Moghaddam, LG Occhipinti, CR Lowe Trends in biotechnology 37 (7), 775-788, 2019 | 19 | 2019 |
| Amino acids whose intracellular levels change most during aging alter chronological life span of fission yeast C Rallis, M Mülleder, G Smith, YZ Au, M Ralser, J Bähler The Journals of Gerontology: Series A 76 (2), 205-210, 2021 | 13 | 2021 |
| KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia YZ Au, M Gu, E De Braekeleer, J Yu, SH Ong, M Gozdecka, X Chen, ... bioRxiv, 2020.04. 25.054049, 2020 | | 2020 |
| The Cell-Essentiality of KAT7 in Acute Myeloid Leukemia YZ Au | | 2020 |
| Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3K13/6) in PTENnull breast cancer S Dunn, J Yu, A Gris-Oliver, J Pilling, P Hoperoft, U Yelland, N Cureton, ... CANCER RESEARCH 79 (13), 2019 | | 2019 |
| Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3Kβ/δ) in PTEN-null breast cancer S Dunn, J Yu, A Gris-Oliver, J Pilling, P Hopcroft, U Yelland, N Cureton, ... Cancer Research 79 (13_Supplement), 321-321, 2019 | | 2019 |
